Butterfly Medical gains EU MDR certification, marking a critical regulatory win that enables the company to launch its proprietary BPH treatment solution throughout Europe.
Butterfly Medical achieved EU MDR certification for its next-generation BPH treatment, enabling market access in Europe and validating its technology.
Butterfly Medical has achieved EU Medical Device Regulation (MDR) certification for its minimally invasive treatment for benign prostatic hyperplasia (BPH). This regulatory milestone validates the company's technology and clears the path for commercial expansion across European markets.
The certification confirms that Butterfly Medical's BPH treatment device meets the rigorous safety and performance requirements mandated by the European Union, allowing the company to market and sell the device within the region.